Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will Successfully Targeting KRAS Change Pancreatic Cancer Treatment?
2
Making Nuanced Decisions on CAR-T and Bispecifics in Multiple Myeloma
3
PROTEUS Trial Design and Key Efficacy Results in Prostate Cancer
4
FDA Grants Priority Review to Dostarlimab in dMMR/MSI-H Rectal Cancer
5